Shots:
- The US FDA has approved Jascayd for the treatment of adults with progressive pulmonary fibrosis (PPF)
- Approval was based on the P-III (FIBRONEER-ILD) trial of Jascayd vs PBO, where Jascayd significantly reduced lung function decline at Wk. 52, with FVC decreases of 86mL (18mg) & 69mL (9mg) vs 152mL with PBO, showing clinically meaningful benefit
- 2EP (composite) showed no significant difference. Exploratory analyses showed reduced acute ILD exacerbations with 18mg, numerically fewer respiratory hospitalizations, & a favorable OS Trend
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim |Press Release
Related News: Boehringer Ingelheim Receives the NMPA Approval of Jascayd (Nerandomilast) for Progressive Pulmonary Fibrosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
